Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Thalassemia International Prognostic Scoring System (TIPSS).
Vitrano A, Musallam KM, Meloni A, Karimi M, Daar S, Ricchi P, Costantini S, Vlachaki E, Di Marco V, El-Beshlawy A, Hajipour M, Ansari SH, Filosa A, Ceci A, Singer ST, Naserullah ZA, Pepe A, Cademartiri F, Pollina SA, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A; International Working Group on Thalassemia (IWG-THAL). Vitrano A, et al. Among authors: pepe a. Blood Cells Mol Dis. 2023 Mar;99:102710. doi: 10.1016/j.bcmd.2022.102710. Epub 2022 Nov 25. Blood Cells Mol Dis. 2023. PMID: 36463683 Review.
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P. Lai ME, et al. Among authors: pepe a. Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9. doi: 10.1016/j.bcmd.2010.05.005. Epub 2010 Jun 17. Blood Cells Mol Dis. 2010. PMID: 20678715
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. Pepe A, et al. Haematologica. 2011 Jan;96(1):41-7. doi: 10.3324/haematol.2009.019042. Epub 2010 Sep 30. Haematologica. 2011. PMID: 20884710 Free PMC article.
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C. Pantalone GR, et al. Among authors: pepe a. Hemoglobin. 2011;35(3):206-16. doi: 10.3109/03630269.2011.570674. Hemoglobin. 2011. PMID: 21599433 Clinical Trial.
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P. Pepe A, et al. J Cardiovasc Magn Reson. 2013 Jan 16;15(1):1. doi: 10.1186/1532-429X-15-1. J Cardiovasc Magn Reson. 2013. PMID: 23324167 Free PMC article.
582 results